Swiss biopharmaceutical company AC Immune said its development partner, Life Molecular Imaging, is moving its PET tracer PI-2620 for imaging tau in Alzheimer's disease into late-stage clinical development.
AC Immune's proprietary Morphomer platform enabled the discovery of PI-2620 in a research collaboration with Life Molecular. Tau aggregates are an important indicator of neuronal death and correlate strongly with cognitive decline.
As part of the agreement with AC Immune, Life Molecular will make a milestone payment. No other details were disclosed.
